Related Experiment Video
Updated: Aug 19, 2026
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Heat shock protein 90 is a rational molecular target in breast cancer
1Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, 9610 Medical Center Drive, Suite 300, Rockville, MD 20850, USA. len@helix.nih.gov
Abstract:
Heat shock protein 90 is a molecular chaperone whose association is required for stability and function of multiple mutated, chimeric, and over-expressed signaling proteins that promote cancer cell growth and/or survival. Hsp90 client proteins important in breast cancer include the estrogen receptor, the serine-threonine kinases Raf-1 and Akt, the receptor tyrosine kinase ErbB2/Neu, and the hypoxia inducible transcription factor HIF-1alpha. Hsp90 small molecule inhibitors, by interacting specifically with a single molecular target, thus promote the destabilization and eventual degradation of multiple cancer cell survival and growth promoting proteins, and these inhibitors have shown promising anti-tumor activity in preclinical breast cancer model systems. One Hsp90 inhibitor, 17-AAG, is currently in Phase I clinical trial. Because of their unique ability to inhibit multiple survival pathways utilized by cancer cells, combination of Hsp90 inhibitors with standard chemotherapeutic agents may dramatically increase in vivo efficacy.
Insights
Heat shock protein 90 (Hsp90) inhibitors destabilize cancer-promoting proteins. These novel cancer therapies show promise in preclinical models and may enhance chemotherapy efficacy.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Heat shock protein 90 (Hsp90) is a molecular chaperone essential for the stability and function of numerous signaling proteins that drive cancer cell growth and survival.
- Key Hsp90 client proteins in breast cancer include estrogen receptor, Raf-1, Akt, ErbB2/Neu, and HIF-1alpha.
Purpose of the Study:
- To investigate the therapeutic potential of Hsp90 small molecule inhibitors in cancer treatment.
- To explore the mechanism of Hsp90 inhibitors in promoting the degradation of cancer-promoting proteins.
- To evaluate the efficacy of Hsp90 inhibitors in preclinical breast cancer models and their potential combination with standard therapies.
Main Methods:
- Utilized Hsp90 small molecule inhibitors designed to interact with a single molecular target.
- Assessed the impact of inhibitors on the destabilization and degradation of multiple client proteins.
- Evaluated anti-tumor activity in preclinical breast cancer model systems.
Main Results:
- Hsp90 inhibitors promote the destabilization and degradation of multiple proteins crucial for cancer cell survival and growth.
- Promising anti-tumor activity was observed in preclinical breast cancer models.
- One Hsp90 inhibitor, 17-AAG, is currently undergoing Phase I clinical trials.
Conclusions:
- Hsp90 inhibitors represent a promising therapeutic strategy by targeting multiple cancer survival pathways simultaneously.
- Combination therapy of Hsp90 inhibitors with standard chemotherapeutic agents may significantly enhance in vivo anti-cancer efficacy.
- Further clinical investigation of Hsp90 inhibitors is warranted for breast cancer and potentially other malignancies.
